PT-141 microdosing: what the label says

A question that circulates in peptide forums is whether PT-141 (bremelanotide) can be taken in small daily amounts, often around 200 micrograms, so the effect accumulates and the nausea that shows up at larger amounts stays away. There is no evidence base for that schedule. The only approved bremelanotide product is dosed on demand at 1.75 mg, in one narrowly defined patient group, and the lowest amount ever taken into a published controlled trial is nearly four times a 200 microgram dose. Here is what the label and the trials actually specify.

What the approved label specifies, and for whom

Vyleesi is the brand name for bremelanotide, the same molecule sold online as PT-141^[5]. The prescribing information states that it is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)^[1]. The same document adds that it is not indicated for the treatment of HSDD in postmenopausal women or in men^[1]. That is the entire approved population.

On dosing, the label specifies 1.75 mg administered subcutaneously in the abdomen or thigh, at least 45 minutes before anticipated sexual activity, supplied as a single-dose autoinjector containing 1.75 mg in 0.3 mL^[1]. It states that no more than one dose should be given within 24 hours, that more than 8 doses per month is not recommended, and that treatment should be discontinued after 8 weeks if the patient does not report an improvement^[1]. Every number on that page describes an on-demand product used before an event, not a standing daily dose.

A daily schedule is not a smaller version of the approved one

A 200 microgram daily regimen changes two variables at once. It cuts the per-dose amount to under an eighth of the approved 1.75 mg, and it raises the number of administrations to roughly 30 a month against a label that stops recommending anything above 8. Neither of those settings has been tested against placebo in any trial we were able to verify. Describing it as a smaller dose of an approved drug understates how far it sits from the studied product.

The key evidence comes from the RECONNECT programme, two identically designed randomised, double-blind, placebo-controlled phase 3 trials published by Kingsberg and colleagues in Obstetrics & Gynecology in 2019. The trials enrolled 1,267 premenopausal women, with 1,202 in the efficacy analysis, and administered 1.75 mg bremelanotide or placebo subcutaneously over 24 weeks^[2]. Improvement on the Female Sexual Function Index desire domain was 0.30 points in study 301 and 0.42 points in study 302, both at P less than .001^[2]. Those are statistically significant and small. They were produced by on-demand dosing at the full amount, and they do not transfer to a different schedule.

Lower doses were tested once, and 200 micrograms was not among them

There is exactly one published dose-ranging trial. Clayton and colleagues, writing in Women's Health (Lond) in 2016, randomised premenopausal women to 0.75 mg, 1.25 mg or 1.75 mg of subcutaneous bremelanotide used as desired over 12 weeks, or to placebo, with 327 in the efficacy analysis^[3]. The published efficacy comparison pooled the 1.25 mg and 1.75 mg arms against placebo: satisfying sexual events per month rose 0.7 versus 0.2 (p=0.0180), Female Sexual Function Index total score rose 3.6 versus 1.9 (p=0.0017), and the Female Sexual Distress Scale score fell 11.1 versus 6.8 (p=0.0014)^[3]. The 0.75 mg arm was not part of that pooled comparison, and 1.75 mg is the amount that went forward to phase 3 and to approval.

So the smallest amount any sponsor thought worth putting in front of a randomised control group was 0.75 mg. A 200 microgram dose is roughly a quarter of that, and 400 micrograms is roughly half. The forum reasoning runs the other way, treating the absence of nausea as a sign the amount is working. Tolerability at a low dose is not a measure of effect. It is equally consistent with the dose doing nothing at all.

The adverse effects the label does document

Nausea is the dominant one. The label reports it in 40% of treated patients against 1.3% on placebo, with flushing at 20.3% versus 0.3%, injection site reactions at 13.2% versus 8.4%, headache at 11.3% versus 1.9%, and vomiting at 4.8% versus 0.2%^[1]. A phase 4 study tested whether pre-treatment with oral ondansetron 30 minutes beforehand would reduce that nausea. It did not, and the label states the practice is not recommended^[1].

The blood pressure signal is why the frequency ceiling exists. The label records maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose and usually back to baseline within 12 hours^[1]. Uncontrolled hypertension and known cardiovascular disease are contraindications^[1]. Focal hyperpigmentation of the face, gingiva and breasts was reported in 1% of patients receiving up to 8 doses per month, was more likely in patients with dark skin, and resolution after stopping was not confirmed in all patients^[1]. That 1% figure is attached to the label's own monthly ceiling. A daily schedule sits outside the exposure the figure describes, so it does not carry over.

What we do not yet know

No published controlled trial has administered bremelanotide on a fixed daily schedule. Both the phase 3 programme and the dose-ranging study dosed it as needed^[2][3]. A 2026 systematic review and meta-analysis in the Journal of Minimally Invasive Gynecology found that bremelanotide improved total Female Sexual Function Index score along with the desire and arousal subscales, and noted that no study directly compared cognitive behavioural therapy with drug treatment^[4]. All of that evidence sits at the approved dose, in women, inside the approved indication. Nothing characterises what a sub-label daily amount does to desire, to blood pressure over repeated exposure, or to pigmentation risk.

This article is educational. It reports what the prescribing information and the published trials state, and it does not advise on sourcing, dosing or using bremelanotide in any context. Vials sold online as research-grade PT-141 are not the approved product and carry no label at all. For the legal picture where you live, see the United States regulation page, the United Kingdom page and the German page. For the pharmacology and the approval history, see the PT-141 peptide page and its regulatory status section. If low sexual desire is causing you distress, that is a conversation for a clinician who can take a history, not for a vial bought online.